Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial

Alla Sikorskii, Gwen K Wyatt, Azfar-E-Alam Siddiqi, Deimante Tamkus, Alla Sikorskii, Gwen K Wyatt, Azfar-E-Alam Siddiqi, Deimante Tamkus

Abstract

More than 80% of women with breast cancer are now reported to be using complementary and alternative medicine (CAM) therapies during conventional treatment. A randomized clinical trial (RCT) of reflexology with late stage breast cancer patients serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of reflexology; (ii) the differences between those who completed the baseline interview and those who dropped out before baseline; and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer, were on chemotherapy or hormonal therapy, and had a PPS of 11 or less. Comparisons of those who dropped out early (N = 33) to those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t-, chi-squared and Fisher's exact tests. The reasons of being "too sick" or "overwhelmed" were given by less than 12% of the women who refused to participate. There was a higher early dropout rate among black women compared to other (primarily white) women (P = .01). Cancer recurrence and metastasis, age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women remain in the trial once consented. Women with advanced disease were likely to enter and remain in the trial despite deterioration in health.

Figures

Figure 1
Figure 1
Flowchart of the study.

References

    1. American Cancer Society. Breast Cancer Facts and Figures, 2007-2008. May 2009, .
    1. Dow KH, Lafferty P. Quality of life, survivorship, and psychosocial adjustment of young women with breast cancer after breast-conserving surgery and radiation therapy. Oncology Nursing Forum. 2000;27:1555–1564.
    1. Irvine D, Brown B, Crooks D, Roberts J, Browne G. Psychosocial adjustment in women with breast cancer. Cancer. 1991;67(4):1097–1117.
    1. Omne-Pontén M, Holmberg L, Sjödén P-O. Psychosocial adjustment among women with breast cancer stages I and II: six-year follow-up of consecutive patients. Journal of Clinical Oncology. 1994;12(9):1778–1782.
    1. McMillan SC, Small BJ. Symptom distress and quality of life in patients with cancer newly admitted to hospice home care. Oncology Nursing Forum. 2002;29(10):1421–1428.
    1. Wyatt GK, Donze LF, Beckrow KC. Efficacy of an in-home nursing intervention following short-stay breast cancer surgery. Research in Nursing and Health. 2004;27(5):322–331.
    1. Morris KT, Johnson N, Homer L, Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. The American Journal of Surgery. 2000;179:407–411.
    1. Hann DM, Baker F, Roberts CS, et al. Use of complementary therapies among breast and prostate cancer patients during treatment: a multisite study. Integrative Cancer Therapies. 2005;4(4):294–300.
    1. Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Women’s Health. 2007;7, article 4
    1. Jordhøy MS, Kaasa S, Fayers P, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliative Medicine. 1999;13(4):299–310.
    1. Young AF, Powers JR, Bell SL. Attrition in longitudinal studies: who do you lose? Australian and New Zealand Journal of Public Health. 2006;30(4):353–361.
    1. Ziegler R. Mistletoe preparation iscador: are there methodological concerns with respect to controlled clinical trials? Evidence-Based Complementary and Alternative Medicine. 2009;6(1):19–30.
    1. Hyman MA. The evolution of research: meeting the needs of systems medicine—part I. Alternative Therapies in Health and Medicine. 2006;12(3):10–11.
    1. Last JM. International Epidemiological Association: A Dictionary of Epidemiology. 4th edition. New York, NY, USA: Oxford University Press; 2001.
    1. Gordis L. Epidemiology. Philadelphia, Pa, USA: Saunders; 2004.
    1. Rothman KJ, Greenland S. Modern Epidemiology. 2nd edition. Philadelphia, Pa, USA: Lippincott-Raven; 1998.
    1. Twisk J, De Vente W. Attrition in longitudinal studies: how to deal with missing data. Journal of Clinical Epidemiology. 2002;55(4):329–337.
    1. Friedman LM, Furberg C, DeMets DL. Fundamentals of Clinical Trials. Littleton, Mass, USA: PSG Publishing Company; 1981.
    1. Li JY, Zhang YF, Smith G, et al. Quality of reporting of randomized controlled trials in Tai Chi interventions: a systematic review. Evidence-Based Complementary and Alternative Medicine. In press.
    1. Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Controlled Clinical Trials. 1997;18(4):328–352.
    1. Cabral DN, Nápoles-Springer AM, Miike R, et al. Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study. American Journal of Epidemiology. 2003;158:272–279.
    1. Bender BG, Ellison MC, Gleason M, Murphy JR, Sundstrom DA, Szefler SJ. Minimizing attrition in a long-term clinical trial of pediatric asthma. Annals of Allergy, Asthma and Immunology. 2003;91(2):168–176.
    1. Krishnan E, Murtagh K, Bruce B, Cline D, Singh G, Fries JF. Attrition bias in rheumatoid arthritis databanks: a case study of 6346 patients in 11 databanks and 65,649 administrations of the Health Assessment Questionnaire. Journal of Rheumatology. 2004;31(7):1320–1326.
    1. Neumark DE, Stommel M, Given CW, Given BA. Research design and subject characteristics predicting nonparticipation in a panel survey of older families with cancer. Nursing Research. 2001;50:363–368.
    1. Honas JJ, Early JL, Frederickson DD, O’Brien MS. Predictors of attrition in a large clinic-based weight-loss program. Obesity Research. 2003;11(7):888–894.
    1. Van Beijsterveldt CEM, Van Boxtel MPJ, Bosma H, Houx PJ, Buntinx F, Jolles J. Predictors of attrition in a longitudinal cognitive aging study: the Maastricht Aging Study (MAAS) Journal of Clinical Epidemiology. 2002;55(3):216–223.
    1. Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. Cancer Detection and Prevention. 2006;30(1):24–33.
    1. Issakidis C, Andrews G. Pretreatment attrition and dropout in an outpatient clinic for anxiety disorders. Acta Psychiatrica Scandinavica. 2004;109(6):426–433.
    1. Sugisawa H, Kishino H, Sugihara Y, Shibata H. Characteristics of dropouts and participants in a twelve-year longitudinal research of Japanese elderly. Nippon Koshu Eisei Zasshi. 2000;47(4):337–349.
    1. Wilson AJE, III, Weber IL. Attrition in a longitudinal study of an aged population. Experimental Aging Research. 1976;2(5):367–387.
    1. Wolinsky FD, Armbrecht ES, Wyrwich KW. Rethinking functional limitation pathways. Gerontologist. 2000;40(2):137–146.
    1. Zeller M, Kirk S, Claytor R, et al. Predictors of attrition from a pediatric weight management program. Journal of Pediatrics. 2004;144(4):466–470.
    1. Mihelic AH, Crimmins EM. Loss to follow-up in a sample of Americans 70 years of age and older: the LSOA 1984–1990. Journals of Gerontology, Series B. 1997;52(1):S37–S48.
    1. Senn S. Statistical Issues in Drug Development. 2nd edition. Chichester, UK: John Wiley & Sons; 2007.
    1. Pirovano M, Maltoni M, Nanni O, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Journal of Pain and Symptom Management. 1999;17(4):231–239.
    1. Glare PA, Sinclair CT. Palliative medicine review: prognostication. Journal of Palliative Medicine. 2008;11(1):84–103.
    1. Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Journal of Pain and Symptom Management. 1999;17(4):240–247.
    1. Glare P, Virik K. Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service. Journal of Pain and Symptom Management. 2001;22(5):891–898.
    1. Glare P, Eychmueller S, McMahon P. Diagnostic accuracy of the palliative prognostic score in hospsitalized patients with advanced cancer. Journal of Clinical Oncology. 2004;22:4823–4828.
    1. Siddiqi A, Sikorskii A, Given CW, Given B. Early participant attrition from clinical trials: role of trial design and logistics. Clinical Trials. 2008;5(4):328–335.
    1. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. Journal of Clinical Oncology. 1984;2(3):187–193.
    1. SAS Software. Version 9 of the SAS System for Windows. Cary, NC, USA: SAS Institute Inc.; 2002-2003.
    1. Fair AM, Wujcik D, Lin JM, Egan KM, Grau AM, Zheng W. Timing is everything: methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research. Contemporary Clinical Trials. 2008;29:537–546.
    1. Stone CA, Tiernan E, Dooley BA. Prospective validation of the palliative prognostic index in patients with cancer. Journal of Pain and Symptom Management. 2008;35(6):617–622.
    1. Robinson J, Biley FC, Dolk H. Therapeutic touch for anxiety disorders. Cochrane Database of Systematic Reviews. 2007;(3) Article ID CD006240.
    1. So PS, Jiang Y. Touch therapies for pain relief in children and adults (Protocol) Cochrane Database of Systematic Reviews. 2008;4 Article ID CD006535.
    1. Efficace F, Horneber M, Lejeune S, et al. Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. Journal of Clinical Epidemiology. 2006;59(12):1257–1265.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅